Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Mesenchymal stromal cells in the prophylaxis of graft vs host disease: A meta analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

GSG. SrinivasanHSHaran Srinivasan SaravananKVKrishna teja Vemulaghat

Discussion

Loading...

Member takes

Overview

Meta-analysis shows MSC infusion reduces acute graft-vs-host disease in HSCT, implying better transplant outcomes.

Key Points

  • MSC infusion significantly lowered the incidence of acute graft-versus-host disease compared to controls.
  • In three trials with 464 participants, MSC recipients showed 16.47% aGVHD occurrence versus 41.17% in control subjects.
  • Optimized analysis via meta-analysis and risk ratio calculations revealed significant benefits in GVHD outcomes.
  • This data supports adopting MSCs as a prophylactic strategy in allogeneic HSCT to improve transplant success.

Cite This Study

Srinivasan et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d631https://doi.org/10.1182/blood-2025-7773
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mesenchymal stromal cells for the prophylaxis of graft-versus-host disease after hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials2025 · 1 citations
  2. 2An optimized MSC product promotes GvHD prophylaxis through exosome-mediated regulatory T cell induction2025 · 1 citations
  3. 3Immunological mechanisms underlying the novel application of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) in graft-versus-host disease (GvHD) therapy2025 · 3 citations
  4. 4Mesenchymal stem cells for the adjunctive treatment of cytomegalovirus pneumonia in hematopoietic stem cell transplant recipients: a Single-center prospective study2025 · 1 citations
  5. 5Mesenchymal stem cells for treating gastrointestinal-involved steroid-refractory acute graft-versus-host disease: A multicenter, single-arm, pivotal clinical Trial2025